W. Storms
Aug 23, 2007
Citations
0
Influential Citations
41
Citations
Quality indicators
Journal
Expert Opinion on Pharmacotherapy
Abstract
Montelukast sodium (Singulair®, Merck and Co., Inc., Whitehouse Station, NJ) is a selective and orally-active leukotriene receptor antagonist with demonstrated effectiveness for treating allergic asthma and allergic rhinitis in adults and children as young as 12 months of age for allergic asthma and 6 months of age for allergic rhinitis. It was recently approved in the US for prevention of exercise-induced bronchoconstriction in patients who are ≥ 15 years of age. This paper updates a prior review of the data on the clinical efficacy of montelukast published in this journal.